A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

This study is testing a medication called talazoparib to see if it can stop advanced cancer cells from repairing themselves, causing them to die. By focusing on patients with specific DNA repair gene mutations, researchers hope to find more effective ways to treat difficult cancers.

This trial is for adults with advanced solid tumors, such as breast, prostate, stomach, ovarian, or pancreatic cancer, that have specific genetic changes. You must have a confirmed mutation in your DNA repair genes, like BRCA1 or BRCA2, and have already tried other treatments.

Participants will take talazoparib, an oral medication, and undergo regular health monitoring. This includes blood tests, tissue biopsies to check your tumor, and imaging scans like X-rays or MRIs to see how the cancer is responding.

The study is currently recruiting patients and is taking place in Gainesville, Florida, and Bethesda, Maryland. Please speak with your doctor to see if one of these locations is an option for you.